Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307759 | 0.83 | KDR (0.44) | ADRA2BKMT2AMEN1MAPTLMNA | |
| SCHEMBL2295562 | 0.83 | LMNA (0.48) | ADRA2BKMT2AMEN1MAPTLMNA | |
| SCHEMBL5303427 | 0.82 | BCHE (0.51) | ADRA2BKMT2AMEN1MAPTLMNA | |
| SCHEMBL2297605 | 0.81 | SMN1; SMN2 (0.52) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL5301613 | 0.81 | PRNP (0.47) | ADRA2BMAPTLMNASMN1; SMN2PRNP | |
| SCHEMBL2297333 | 0.81 | ADRA2B (0.49) | ADRA2BMAPTLMNASMN1; SMN2PRNP | |
| SCHEMBL2291392 | 0.80 | KMT2A (0.51) | KMT2AMEN1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL5300929 | 0.80 | KMT2A (0.51) | ADRA2BKMT2AMEN1MAPTLMNA | |
| SCHEMBL2291248 | 0.80 | USP2 (0.51) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL5300999 | 0.79 | SMN1; SMN2 (0.50) | KMT2AMEN1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |